Filana Therapeutics (FLNA) Change in Accured Expenses (2010 - 2026)

Filana Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $102000.0 for Q2 2026.

• In Q2 2026, Change in Accured Expenses fell 99.71% year-over-year to $102000.0; the TTM figure through Jun 2026 stood at -$37.3 million (down 558.93% YoY), while the FY2025 annual figure was $268000.0, down 76.84% from the prior year.
• Change in Accured Expenses for Q2 2026 stood at $102000.0, up from -$2.5 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $42.9 million in Q2 2024, with the low at -$40.5 million in Q4 2024.
• The 5-year median for Change in Accured Expenses is -$103000.0 (2024), against an average of -$163444.4.
• Peak annual rise in Change in Accured Expenses reached 1949.09% in 2024, while the deepest fall reached 562.1% in 2024.
• Filana Therapeutics' Change in Accured Expenses stood at $1.9 million in 2022, then tumbled by 424.62% to -$6.1 million in 2023, then slumped by 562.1% to -$40.5 million in 2024, then grew by 6.55% to -$37.9 million in 2025, then surged by 100.27% to $102000.0 in 2026.
• Business Quant data shows FLNA's Change in Accured Expenses at $102000.0 in Q2 2026, -$2.5 million in Q1 2026, and -$37.9 million in Q4 2025.